Actively Recruiting
Study of Dextromethorphan in OCD and Related Disorders
Led by Stanford University · Updated on 2025-08-27
60
Participants Needed
1
Research Sites
253 weeks
Total Duration
On this page
Sponsors
S
Stanford University
Lead Sponsor
A
Avy L. & Roberta L. Miller Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of the study is to assess the tolerability and efficacy of dextromethorphan in combination with fluoxetine for symptom relief in OCD and related disorders.
CONDITIONS
Official Title
Study of Dextromethorphan in OCD and Related Disorders
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of obsessive-compulsive disorder (OCD), body dysmorphic disorder (BDD), illness anxiety disorder (IAD) or somatic symptom disorder (SSD)
- Living within California
- Capacity to provide informed consent
You will not qualify if you...
- Current bipolar disorder or psychotic disorder
- Active moderate or severe substance use disorder, lifetime severe substance use disorder
- Pregnant or nursing women
- Use of prescribed psychotropic medications other than fluoxetine for 2 weeks prior to study start
- Having commenced OCD-targeted exposure and response-prevention (ExRP) psychotherapy within 2 months of study start
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Stanford University
Stanford, California, United States, 94304
Actively Recruiting
Research Team
P
Pavithra Mukunda, MS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here